GLUCOSULFONE

US Previously Marketed

First approved in 1945

Details

Stereochemistry	MIXED
Molecular Formula	C24H36N2O18S3
Molecular Weight	736.74
Optical Activity	UNSPECIFIED
Defined Stereocenters	8 / 10
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(NC1=CC=C(C=C1)S(=O)(=O)C2=CC=C(NC([C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)S(O)(=O)=O)C=C2)S(O)(=O)=O

InChI

InChIKey=SQQCWHCJRWYRLB-AGNGBHFPSA-N

InChI=1S/C24H36N2O18S3/c27-9-15(29)17(31)19(33)21(35)23(46(39,40)41)25-11-1-5-13(6-2-11)45(37,38)14-7-3-12(4-8-14)26-24(47(42,43)44)22(36)20(34)18(32)16(30)10-28/h1-8,15-36H,9-10H2,(H,39,40,41)(H,42,43,44)/t15-,16-,17-,18-,19+,20+,21-,22-,23?,24?/m1/s1

HIDE SMILES / InChI

Molecular Formula	C24H36N2O18S3
Molecular Weight	736.74
Charge	0
Count

Stereochemistry	MIXED
Additional Stereochemistry	No
Defined Stereocenters	8 / 10
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://pubchem.ncbi.nlm.nih.gov/compound/Glucosulfone | https://pubchem.ncbi.nlm.nih.gov/compound/Promin | https://www.ncbi.nlm.nih.gov/pubmed/8251346

Glucosulfone (Glucosulfone Free Acid, or Promin) is a compound used to treat mycobacterial infections, such as tuberculosis and leprosy. It is converted to dapsone in the body, which also has been shown to have therapeutic effects against dermatitis herpetiformis, actinomycotic mycetoma, asthma, malaria, rheumatoid arthritis, Kaposiís sarcoma, pneumocystis carinii (pneumonia), subcorneal pustular dermatosis and cystic acne. Once converted to dapsone, it has haemotoxic effects (destroying red blood cells, or disrupting blood clotting, potentially causing organ or tissue damage).

Approval Year

Doses

Dose	Population	Adverse events
5 g 1 times / day multiple, intravenous Studied dose Dose: 5 g, 1 times / day Route: intravenous Route: multiple Dose: 5 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5950351/	unhealthy, adult n = 68 Health Status: unhealthy Condition: leprosy Age Group: adult Sex: M+F Population Size: 68 Sources: https://pubmed.ncbi.nlm.nih.gov/5950351/	Disc. AE: Allergic dermatitis... Other AEs: Anemia, Leucopenia... AEs leading to discontinuation/dose reduction: Allergic dermatitis (3%) Other AEs: Anemia (46%) Leucopenia (3%) Allergic dermatitis (16%) Allergic rhinitis (1.5%) Headache (grade 1) Nausea (grade 1, 35%) Vomiting (7%) Erythema nodosum leprosum (3%) Iridocyclitis (10%) Lymphadenitis (1.5%) Sources: https://pubmed.ncbi.nlm.nih.gov/5950351/

AEs

AE	Significance	Dose	Population
Allergic rhinitis	1.5%	5 g 1 times / day multiple, intravenous Studied dose Dose: 5 g, 1 times / day Route: intravenous Route: multiple Dose: 5 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5950351/	unhealthy, adult n = 68 Health Status: unhealthy Condition: leprosy Age Group: adult Sex: M+F Population Size: 68 Sources: https://pubmed.ncbi.nlm.nih.gov/5950351/
Lymphadenitis	1.5%	5 g 1 times / day multiple, intravenous Studied dose Dose: 5 g, 1 times / day Route: intravenous Route: multiple Dose: 5 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5950351/	unhealthy, adult n = 68 Health Status: unhealthy Condition: leprosy Age Group: adult Sex: M+F Population Size: 68 Sources: https://pubmed.ncbi.nlm.nih.gov/5950351/
Iridocyclitis	10%	5 g 1 times / day multiple, intravenous Studied dose Dose: 5 g, 1 times / day Route: intravenous Route: multiple Dose: 5 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5950351/	unhealthy, adult n = 68 Health Status: unhealthy Condition: leprosy Age Group: adult Sex: M+F Population Size: 68 Sources: https://pubmed.ncbi.nlm.nih.gov/5950351/
Allergic dermatitis	16%	5 g 1 times / day multiple, intravenous Studied dose Dose: 5 g, 1 times / day Route: intravenous Route: multiple Dose: 5 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5950351/	unhealthy, adult n = 68 Health Status: unhealthy Condition: leprosy Age Group: adult Sex: M+F Population Size: 68 Sources: https://pubmed.ncbi.nlm.nih.gov/5950351/
Erythema nodosum leprosum	3%	5 g 1 times / day multiple, intravenous Studied dose Dose: 5 g, 1 times / day Route: intravenous Route: multiple Dose: 5 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5950351/	unhealthy, adult n = 68 Health Status: unhealthy Condition: leprosy Age Group: adult Sex: M+F Population Size: 68 Sources: https://pubmed.ncbi.nlm.nih.gov/5950351/
Leucopenia	3%	5 g 1 times / day multiple, intravenous Studied dose Dose: 5 g, 1 times / day Route: intravenous Route: multiple Dose: 5 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5950351/	unhealthy, adult n = 68 Health Status: unhealthy Condition: leprosy Age Group: adult Sex: M+F Population Size: 68 Sources: https://pubmed.ncbi.nlm.nih.gov/5950351/
Allergic dermatitis	3% Disc. AE	5 g 1 times / day multiple, intravenous Studied dose Dose: 5 g, 1 times / day Route: intravenous Route: multiple Dose: 5 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5950351/	unhealthy, adult n = 68 Health Status: unhealthy Condition: leprosy Age Group: adult Sex: M+F Population Size: 68 Sources: https://pubmed.ncbi.nlm.nih.gov/5950351/
Anemia	46%	5 g 1 times / day multiple, intravenous Studied dose Dose: 5 g, 1 times / day Route: intravenous Route: multiple Dose: 5 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5950351/	unhealthy, adult n = 68 Health Status: unhealthy Condition: leprosy Age Group: adult Sex: M+F Population Size: 68 Sources: https://pubmed.ncbi.nlm.nih.gov/5950351/
Vomiting	7%	5 g 1 times / day multiple, intravenous Studied dose Dose: 5 g, 1 times / day Route: intravenous Route: multiple Dose: 5 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5950351/	unhealthy, adult n = 68 Health Status: unhealthy Condition: leprosy Age Group: adult Sex: M+F Population Size: 68 Sources: https://pubmed.ncbi.nlm.nih.gov/5950351/
Headache	grade 1	5 g 1 times / day multiple, intravenous Studied dose Dose: 5 g, 1 times / day Route: intravenous Route: multiple Dose: 5 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5950351/	unhealthy, adult n = 68 Health Status: unhealthy Condition: leprosy Age Group: adult Sex: M+F Population Size: 68 Sources: https://pubmed.ncbi.nlm.nih.gov/5950351/
Nausea	grade 1, 35%	5 g 1 times / day multiple, intravenous Studied dose Dose: 5 g, 1 times / day Route: intravenous Route: multiple Dose: 5 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5950351/	unhealthy, adult n = 68 Health Status: unhealthy Condition: leprosy Age Group: adult Sex: M+F Population Size: 68 Sources: https://pubmed.ncbi.nlm.nih.gov/5950351/

Sourcing

Vendor/Aggregator	ID	URL
ABI Chem	AC1LAFKP
BOC Sciences	554-18-7
Compound Cloud	10440240
Compound Cloud	487090
NovoSeek	10440240
THE BioTek	bt-447769	https://www.thebiotek.com/product/others/bt-447769
ZINC	ZINC000008214572	http://zinc15.docking.org/substances/ZINC000008214572
ZINC	ZINC000095628283	http://zinc15.docking.org/substances/ZINC000095628283
ZINC	ZINC000095628284	http://zinc15.docking.org/substances/ZINC000095628284
eMolecules	110040929

Patents

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:41:03 GMT 2023` Edited by `admin` on `Fri Dec 15 15:41:03 GMT 2023`
Record UNII	JX8G4WPC8D
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

GLUCOSULFONE

Common Name

English

GLUCOSULFONE FREE ACID

Common Name

English

GLUCOSULFONE [MART.]

Common Name

English

GLUCOSULPHONE FREE ACID

Common Name

English

SN-166 FREE ACID

Code

English

4,4'-DIAMINOPHENYLSULFONE-N,N-DI(DEXTROSE SULFONATE)

Common Name

English

Glucosulfone [WHO-DD]

Common Name

English

D-GLUCITOL, 1,1'-(SULFONYLBIS(4,1-PHENYLENEIMINO))BIS(1-DEOXY-1-SULFO-

Common Name

English

4,4'-DIAMINOPHENYLSULPHONE-N,N-DI(DEXTROSE SULPHONATE)

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C849